x

WHO Validates China’s COVID-19 Vaccine, Sinovac, For Emergency Use

World Health Organisation (WHO) has validated the Sinovac-CoronaVac COVID-19 vaccine for emergency use.

WHO, in a statement, said that the validation gives countries, funders, procuring agencies and communities the assurance that it meets international standards for safety, efficacy and manufacturing.

Sinovac-CoronaVac vaccine is produced by the Beijing-based pharmaceutical company, Sinovac.

WHO has earlier listed the Pfizer/BioNTech, Astrazeneca-SK Bio, Serum Institute of India, Astra Zeneca EU, Janssen, Moderna and Sinopharm vaccines for emergency use.

The statement quoted Dr Mariângela Simão, WHO Assistant-Director General for Access to Health Products, as saying, “The world desperately needs multiple COVID-19 vaccines to address the huge access inequity across the globe.

“We urge manufacturers to participate in the COVAX Facility, share their knowhow and data and contribute to bringing the pandemic under control.”

WHO’s Emergency Use Listing (EUL) is a prerequisite for COVAX Facility vaccine supply and international procurement. It also allows countries to expedite their own regulatory approval to import and administer COVID-19 vaccines.

The EUL assesses the quality, safety and efficacy of COVID-19 vaccines, as well as risk management plans and programmatic suitability, such as cold chain requirements.

The assessment is performed by the product evaluation group, composed by regulatory experts from around the world and a Technical Advisory Group (TAG), in charge of performing the risk-benefit assessment for an independent recommendation on whether a vaccine can be listed for emergency use and, if so, under which conditions.

In the case of the Sinovac-CoronaVac vaccine, the WHO assessment included on-site inspections of the production facility.

The Sinovac-CoronaVac product is an inactivated vaccine. Its easy storage requirements make it manageable and particularly suitable for low-resource settings.

WHO’s Strategic Advisory Group of Experts on Immunisation (SAGE) has also completed its review of the vaccine.

On the basis of available evidence, WHO recommends the vaccine for use in adults 18 years and older, in a two-dose schedule with a spacing of two to four weeks.

Vaccine efficacy results show that the vaccine prevents symptomatic disease in 51 per cent of those vaccinated and prevents severe COVID-19 and hospitalisation in 100 per cent of the studied population. 

Hot this week

Editors Urge Government To Create Safe, Enabling Environment For Journalists

· Ask security agents to find missing Vanguard journalistAs...

EXCLUSIVE: Buhari orders probe of Isa Funtua, AMCON over keystone and Etisalat

Following the controversy generated by the leading opposition party,...

6 Signs your boyfriend thinks you are ugly -Take note of No. 2

They say there are three kinds of people; the...

2023: South-East, Middle Belt Forum Endorses Peter Obi

The South-East and Middle Belt Forum has endorsed the...

A’Ibom Lawmaker, Edidem, lauds Tinubu over Akpabio’s SSDC appointment

By Ogenyi OgenyiDeputy Speaker of the Akwa Ibom Assembly,...

Dr. Uduak Silas Obot Laid to Rest in His Country Home

Amgbare Ekaunkumo, YenagoaThe remains of Dr. Uduak Silas Obot,...

Bayelsa Governor Lauds Security Agencies for Synergy

Amgbare Ekaunkumo, YenagoaBayelsa State Governor, Senator Douye Diri has...

Bayelsa Cult Attack Claims Two Lives

Amgbare Ekaunkumo, YenagoaTwo Niger Delta University graduates were brutally...

B’Haram: Zulum approves 35 patrol vehicles, motorcycles for Borno community

By Achadu Gabriel, KadunaBorno State Governor, Babagana Umara Zulum,...

Adulterated soya beans oil producing factory discover in Kaduna

By Achadu Gabriel, kadunaApparently owing to severity of hardship...

Judge Faces Compulsory Retirement for Misconduct in Kogi

By Noah Ocheni, LokojaAn area court Judge, Alemeru Adekunle...
spot_img

Related Articles

Popular Categories

spot_imgspot_img